Amedisys (AMED) Tops Q3 EPS by 18c, Raises FY Guidance
Get Alerts AMED Hot Sheet
Price: $91.05 -0.12%
EPS Growth %: +2.0%
Financial Fact:
Income tax expense: -6.69M
Today's EPS Names:
TOWN, NRIM, GCBC, More
EPS Growth %: +2.0%
Financial Fact:
Income tax expense: -6.69M
Today's EPS Names:
TOWN, NRIM, GCBC, More
Join SI Premium – FREE
Amedisys (NASDAQ: AMED) reported Q3 EPS of $0.95, $0.18 better than the analyst estimate of $0.77. Revenue for the quarter came in at $417.3 million versus the consensus estimate of $411.2 million.
GUIDANCE:
Amedisys sees FY2018 EPS of $3.54-$3.60, versus the consensus of $3.40. Amedisys sees FY2018 revenue of $1.65-1.67 billion, versus the consensus of $1.65 billion.
For earnings history and earnings-related data on Amedisys (AMED) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- FS Bancorp (FSBW) Tops Q1 EPS by 8c
- Meritage Homes Corporation (MTH) Tops Q1 EPS by 151c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!